Tag: milestones

SYDNEY, July 29, 2025 (GLOBE NEWSWIRE) -- Global broker Axi proudly announces a major milestone in its trader funding program, Axi Select, as it celebrates its 5^th $1 million funded trader, and surpasses $5 million in profit payouts year-to-date.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS

How to Build Muscle Fast for Beginners And Skinny Guys: with CrazyBulk Muscle-Building Supplements, The Ultimate Guide for 2025

KOŠICE, Slovakia, July 26, 2025 (GLOBE NEWSWIRE) -- Remittix (RTX), a crypto payments platform aiming to simplify cross-border and freelance transactions, has confirmed the Q3 2025 launch of its beta wallet, alongside newly announced integration with the Solana blockchain. These developments mark key milestones in Remittix’s roadmap toward enabling fast, low-cost, and user-friendly crypto-to-fiat payments.

Coinchange Celebrates 4 Years of 'Earn' Product, Marks 7 Years of Growth. The Canadian digital asset management platform reflects on its evolution from retail app to institutional-grade yield infrastructure.

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.

GEELONG, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that Orion Infrastructure Capital ("OIC") has released US$5 million of the US$25 million facility announced on December 23, 2024. As a result of this release, the full US$25 million facility has now been released. Concurrent with this US$5 million tranche, lenders under the US$60 million PIUS loan entered into in May 2023 (“Existing Noteholders”) have also released the final US$400,000 of existing loan reserves, taking reserves released to US$2 million. In connection with this funding tranche, the Company will issue to OIC and Existing Noteholders, penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company’s shares outstanding.